title: Intravitreal ranibizumab for retinal arterial macroaneurysm: long-term results of a prospective study.
abstract: OBJECTIVE
  To evaluate the potential efficacy and safety of primary intravitreal ranibizumab in patients with symptomatic retinal arterial macroaneurysm (RAM).
  
  
  METHODS
  This prospective study comprised 5 eyes with RAM treated with intravitreal ranibizumab. At baseline, all patients underwent best-corrected visual acuity (BCVA) measurement, ophthalmic examination including slit-lamp biomicroscopy, and central foveal thickness (CFT) measurement using optical coherence tomography. Fluorescein angiography was also performed to confirm diagnosis. Patients were examined at 1 month after injection and monthly thereafter. Main outcome measures included changes in BCVA and CFT. Safety was assessed by ophthalmic examination and report of systemic adverse effects.
  
  
  RESULTS
  There was a statistically significant difference in BCVA (p<0.001) and CFT (p<0.001) before and after the ranibizumab injection at the end of the follow-up of 13.4 ± 3.2 months. One injection appeared to be sufficient for the resolution of macular edema and absorption of hemorrhages. No observable ocular or systemic side effects were found. One patient developed foveal atrophy.
  
  
  CONCLUSIONS
  Intravitreal ranibizumab seems to be effective and safe for the treatment of symptomatic RAM.
authors.affiliation: 2 Department of Ophthalmology, Ophthalmiatrion Athinon, Athens - Greece.
authors.forename: Irini
authors.initials: I
authors.lastname: Chatziralli
authors.affiliation: 2 Department of Ophthalmology, Ophthalmiatrion Athinon, Athens - Greece.
authors.forename: Aggeliki
authors.initials: A
authors.lastname: Maniatea
authors.affiliation: 2 Department of Ophthalmology, Ophthalmiatrion Athinon, Athens - Greece.
authors.forename: Kyriakoula
authors.initials: K
authors.lastname: Koubouni
authors.affiliation: 2 Department of Ophthalmology, Ophthalmiatrion Athinon, Athens - Greece.
authors.forename: Efstratios
authors.initials: E
authors.lastname: Parikakis
authors.affiliation: 2 Department of Ophthalmology, Ophthalmiatrion Athinon, Athens - Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Mitropoulos
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000783:Aneurysm / Q000188:drug therapy; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D012164:Retinal Diseases / Q000188:drug therapy* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab